Literature DB >> 19757422

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience.

Anne M Traynor1, Gregory M Richards, Gregory K Hartig, Deepak Khuntia, James F Cleary, Peggy A Wiederholt, Søren M Bentzen, Paul M Harari.   

Abstract

BACKGROUND: We retrospectively examined the treatment efficacy and toxicity profile of intensity-modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
METHODS: A total of 57 patients with stage III or IV HNSCC were treated with IMRT and concurrent weekly cisplatin (dosed at 30 mg/m(2)) between November 2001 and May 2007. The median prescription dose to the gross tumor volume was 70 Gy (using 2.0-2.2 Gy daily fractions).
RESULTS: In-field tumor control at 2 years was 89.1%, locoregional control was 85.5%, and overall survival was 86.9%. The median radiation dose delivered was 70 Gy. The mean dose intensity of cisplatin administered was 25.7 mg/m(2)/week.
CONCLUSION: Comprehensive head and neck IMRT to 70 Gy delivered with weekly cisplatin chemotherapy (30 mg/m(2)) is feasible and generally well tolerated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19757422      PMCID: PMC3028434          DOI: 10.1002/hed.21224

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  30 in total

1.  A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.

Authors:  Nancy Y Lee; Fernando F de Arruda; Dev R Puri; Suzanne L Wolden; Ashwatha Narayana; James Mechalakos; Ennapadam S Venkatraman; Dennis Kraus; Ashok Shaha; Jatin P Shah; David G Pfister; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-15       Impact factor: 7.038

2.  Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma.

Authors:  Megan E Daly; Yeeyie Lieskovsky; Todd Pawlicki; Jervis Yau; Harlan Pinto; Michael Kaplan; Willard E Fee; Albert Koong; Don R Goffinet; Lei Xing; Quynh-Thu Le
Journal:  Head Neck       Date:  2007-03       Impact factor: 3.147

3.  A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas.

Authors:  José Antonio Medina; Antonio Rueda; Antonio Sacchetti de Pasos; Jorge Contreras; Manuel Cobo; Paloma Moreno; Manuel Benavides; Asunción Villanueva; Emilio Alba
Journal:  Radiother Oncol       Date:  2006-04-19       Impact factor: 6.280

Review 4.  Chemoradiotherapy for locally advanced head and neck cancer.

Authors:  Joseph K Salama; Tanguy Y Seiwert; Everett E Vokes
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

5.  Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Jean Bourhis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007       Impact factor: 7.038

6.  Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.

Authors:  Edmond H N Pow; Dora L W Kwong; Anne S McMillan; May C M Wong; Jonathan S T Sham; Lucullus H T Leung; W Keung Leung
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-15       Impact factor: 7.038

7.  Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience.

Authors:  Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-02       Impact factor: 7.038

8.  Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.

Authors:  Min Yao; Kenneth J Dornfeld; John M Buatti; Mark Skwarchuk; Huaming Tan; Thanh Nguyen; Judith Wacha; John E Bayouth; Gerry F Funk; Russell B Smith; Scott M Graham; Kristi Chang; Henry T Hoffman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

Review 9.  Evaluation of early and late toxicities in chemoradiation trials.

Authors:  Søren M Bentzen; Andrea Trotti
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

10.  Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy.

Authors:  Pierre Graff; Michel Lapeyre; Emmanuel Desandes; Cécile Ortholan; René-Jean Bensadoun; Marc Alfonsi; Philippe Maingon; Philippe Giraud; Jean Bourhis; Vincent Marchesi; Alice Mège; Didier Peiffert
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-07       Impact factor: 7.038

View more
  21 in total

Review 1.  Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues.

Authors:  Kranti A Mapuskar; Carryn M Anderson; Douglas R Spitz; Ines Batinic-Haberle; Bryan G Allen; Rebecca E Oberley-Deegan
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

2.  Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience.

Authors:  Nemer Osman; Yasir Y Elamin; Shereen Rafee; Cathal O'Brien; Leo F A Stassen; Conrad Timon; John Kinsella; Sinead Brennan; Kenneth J O'Byrne
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08       Impact factor: 2.503

3.  Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma.

Authors:  Carryn M Anderson; Stephen T Sonis; Christopher M Lee; Douglas Adkins; Bryan G Allen; Wenqing Sun; Sanjiv S Agarwala; Madhavi L Venigalla; Yuhchyau Chen; Weining Zhen; Diane R Mould; Jon T Holmlund; Jeffrey M Brill; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-16       Impact factor: 7.038

Review 4.  Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.

Authors:  Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken
Journal:  Oncologist       Date:  2017-05-22

5.  Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy.

Authors:  Tim J Kruser; Stephanie R Rice; Kevin P Cleary; Heather M Geye; Wolfgang A Tome; Paul M Harari; Kevin R Kozak
Journal:  Technol Cancer Res Treat       Date:  2013-03-26

6.  Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.

Authors:  D Van Gestel; D Van Den Weyngaert; D Schrijvers; J Weyler; J B Vermorken
Journal:  Br J Radiol       Date:  2011-04       Impact factor: 3.039

7.  Status of hydration assessed by bioelectrical impedance analysis: a valuable predictive factor for radiation-induced oral mucositis in head and neck cancer patients.

Authors:  A Brzozowska; R Mlak; P Gołębiowski; T Małecka-Massalska
Journal:  Clin Transl Oncol       Date:  2018-10-16       Impact factor: 3.405

8.  Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382).

Authors:  Harry Quon; Traci Leong; Robert Haselow; Bruce Leipzig; Jay Cooper; Arlene Forastiere
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

9.  Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.

Authors:  Matthew J Nyflot; Tim J Kruser; Anne M Traynor; Deepak Khuntia; David T Yang; Gregory K Hartig; Timothy M McCulloch; Peggy A Wiederholt; Lindell R Gentry; Tien Hoang; Robert Jeraj; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-03       Impact factor: 7.038

10.  Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.

Authors:  Takatsugu Mizumachi; Akihiro Homma; Tomohiko Kakizaki; Tomohiro Sakashita; Satoshi Kano; Hiromitsu Hatakeyama; Kazuhiko Tsuchiya; Koichi Yasuda; Rikiya Onimaru; Hiroki Shirato; Jun Taguchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Akita; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2014-07-05       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.